Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Adstiladrin (nadofaragene firadenovec-vncg)
i
Other names:
rAd-IFN/Syn3, SCH 721015/SCH 209702, Ad-IFNalpha/Syn3, rAd-IFN, TR002, FE 999326
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
FKD Therapies, Ferring, Royalty
Drug class:
IFNα stimulant
Related drugs:
‹
pegylated interferon α -2a (3)
interferon alfa 2b (0)
JZP898 (0)
NG-641 (0)
recombinant interferon alfa-2a (0)
SAR441000 (0)
Autologous CD34+ enriched HSPCs expressing interferon-alpha 2 (0)
peginterferon-α-2b (0)
IGN002 (0)
TAK-573 (0)
pegylated interferon α -2a (3)
interferon alfa 2b (0)
JZP898 (0)
NG-641 (0)
recombinant interferon alfa-2a (0)
SAR441000 (0)
Autologous CD34+ enriched HSPCs expressing interferon-alpha 2 (0)
peginterferon-α-2b (0)
IGN002 (0)
TAK-573 (0)
›
Associations
(1)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Efficacy & Safety of RAd-IFN Administered with Celecoxib & Gemcitabine in Patients with Malignant Pleural Mesothelioma (INFINITE) (NCT03710876)
Phase 3
Ferring Ventures Limited
Ferring Ventures Limited
Active, not recruiting
Phase 3
Ferring Ventures Limited
Active, not recruiting
Last update posted :
11/08/2024
Initiation :
01/21/2019
Primary completion :
03/29/2024
Completion :
04/01/2026
MSLN • EFEMP1
|
gemcitabine • Adstiladrin (nadofaragene firadenovec-vncg) • celecoxib oral
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer (NCT01687244)
Phase 2
FKD Therapies Oy
FKD Therapies Oy
Completed
Phase 2
FKD Therapies Oy
Completed
Last update posted :
07/24/2017
Initiation :
09/01/2012
Primary completion :
10/01/2015
Completion :
01/01/2016
IFNA1
|
IFNA2 elevation
|
Adstiladrin (nadofaragene firadenovec-vncg)
A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816) (NCT00536588)
Phase 1
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Completed
Phase 1
Merck Sharp & Dohme LLC
Completed
Last update posted :
03/27/2015
Initiation :
09/01/2006
Primary completion :
08/01/2009
Completion :
08/01/2009
IFNA1
|
Adstiladrin (nadofaragene firadenovec-vncg)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login